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drug has been recommended as a restricted or authority
required benefit. It has been suggested that prescribing outside
of subsidy-approved indications (i.e. leakage) is a major cause
of the cost increases in the PBS. While such prescribing
certainly does occur, the PBAC has never been in a position,
at the time that a drug is approved for subsidy, to disclose the
evidence on which decisions to include such restrictions were
made or to be able to place the use of the drug in an appropriate
clinical and cost-effective context. The PBAC is hopeful it
will be able to initiate these reforms in the near future.
However, as Professor Eadie clearly points out, there are
matters of ‘commercial-in-confidence’ which must be
acknowledged and attended to, and discussion with the
pharmaceutical industry is essential to address their legitimate
concerns on this and other issues. Notwithstanding these
concerns the overriding consideration must be the right of
doctors and the public to have access to information. It is the
responsibility of regulatory authorities to provide it in a
manner appropriate to each stakeholder group. There is no
doubt that disclosure of information will make the decision
makers more accountable, but that is how it should be in a
transparent system.
The saying ‘Don’t tell me why it cannot be done but
how it can be done’ is appropriate in the context of this
issue. Professor Eadie’s comments are an excellent
starting point.
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Insulins in 2002
Editor, – Regarding insulin and metformin schedules – indeed
one size does not fit all. Dr Pat Phillips’ excellent update
‘Insulins in 2002’ (Aust Prescr 2002;25:29–31) nicely
highlights inter-individual insulin requirements (e.g. a predicted
daily range of 39 to 78 units of insulin for a 78 kg man).
When metformin is factored into the equation, the
considerations become even more complex, as when for
example a patient has mild diabetes-related renal dysfunction
and/or chronic low-grade hepatitis B, both of which are
relative contraindications to the use of metformin.
I am also currently looking after a man in his 70s who is
mildly overweight, with borderline urea and creatinine,
chronic hepatitis B with a slightly raised GGT but normal
ALT concentration. His insulin requirements exceed
100 units per day, but metformin is being withheld out of
concern for potential adverse effects.
In view of the potential value of metformin with insulin,
would Dr Phillips care to comment further on the nuances




Dr P. Phillips, the author of the article, comments:
Dr Philpot correctly points out the advantages of continuing
metformin when starting insulin in patients with type 2
diabetes. Metformin has actions independent of insulin
secretion (by reducing gluconeogenesis and insulin resistance)
and it has benefits in controlling weight.
However, metformin can cause potentially life-threatening
lactic acidosis in patients at risk of metformin accumulation
(renal impairment), hypoxic challenges (respiratory or cardiac
failure) or reduced lactate clearance (impaired liver function).
The first patient described by Dr Philpot had ‘mild diabetes-
related renal dysfunction and/or chronic low-grade
hepatitis B’. If the patient had one relative contraindication
(moderate renal impairment, GFR 30–60 mL/minute) our
guidelines1 would recommend that low doses of metformin
are appropriate (500–1000 mg/day). The situation should be
reviewed regularly and metformin should be stopped if the
patient were to develop an absolute contraindication.
In the second case it appears that the patient might have
moderate renal impairment (GFR 30–60 mL/minute) but no
functional liver impairment. A metformin dose of
500–1000 mg/day would seem appropriate and might reduce
the necessary insulin dose and improve glycaemic control.
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The evidence-relevance gap
Editor, – I was most impressed by the article ‘The evidence-
relevance gap – the example of hormone replacement therapy’
(Aust Prescr 2002;25:60–2) in which Dr Neeskens gives a
sensible and pragmatic approach to dealing with complex
information thereby allowing the patient to put it in context
for her situation. Too often we are confronted with population
studies, but what do they mean to the individual person?
There are two other situations, one involving vast expense
and the other some serious morbidity, which require similar
scrutiny. The first involves the escalating use of ‘statins’ in
the community at a cost which may result in limiting the
ability of the Pharmaceutical Benefits Scheme to afford new
drugs. Should we really be trying to reduce the cholesterol
level to some magic number in every adult Australian, even
those who are asymptomatic and without a relevant family
history? And if so, for how long do we continue this therapy?
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I frequently see patients in the 80–90 year-old age group
presenting for surgery still religiously taking their prescribed
statin. Is this necessary?
Secondly, the prescribing of warfarin with its dangerously
low therapeutic index to prevent some perceived morbidity
too often results in genuine catastrophes in the form of
gastrointestinal or intracranial haemorrhage. Again, elderly
patients present as emergencies requiring scarce blood
products to reverse the coagulation defect before surgery can
be performed. For how long do we keep prescribing this toxic
drug? Presumably once patients have these major morbidities
they are not started on warfarin again, so could it not be





Editor, – Dr Neeskens is to be congratulated for his article
‘The evidence-relevance gap – the example of hormone
replacement therapy’ (Aust Prescr 2002;25:60–2). I hope
it will be a forerunner of articles testing the proposition
that years of taking pharmaceuticals by basically well
(i.e. symptomless people) is a good thing.
I know of no medicine that works which can be taken with
impunity by everyone. We are all that little bit different.
The majority of trials are undertaken on people who have a
problem (I include Framingham: it is surely not healthy to be






Dr Neeskens is currently preparing another article for
Australian Prescriber.
Dental patients receiving warfarin therapy
Editor, – We refer to ‘Dental notes: Managing dental patients
receiving warfarin therapy’ (Aust Prescr 2002;25:69). This
commentary is unfortunate because it presents the historical
approach to managing patients on warfarin therapy and does
not reflect current best practice.
The key issue is the risk:benefit analysis of ceasing warfarin
and risking thromboembolism, versus reducing it and risking
local wound bleeding. Any logical analysis clearly comes
down on the side that if warfarin is indicated and has been
appropriately prescribed, then one should leave it alone. The
real and potential risks such as stroke or myocardial
infarction are clearly catastrophic events, whereas at worst
local wound bleeding is messy and inconvenient.
There is an extensive body of research which shows that the
appropriate management of patients on warfarin who require
dentoalveolar surgery is as follows:
• preoperative – check INR the day before the procedure
to ensure it is within the therapeutic range for the patient. If
greater than 4.0, advise the patient’s physician and delay
surgery until the INR is within the therapeutic range.
• intraoperative – the use of a local anaesthetic combined
with a vasoconstrictor, plus a controlled, minimally
traumatic surgical technique and local haemostatic
methods are recommended. This includes irrigating the
operative field with a 4.8% tranexamic acid solution. The
sockets and mucoperiosteal flaps should then be sutured
and oxidised cellulose gauze placed in the sockets.
• postoperative – the patients should be given a 4.8%
tranexamic acid mouthwash with instructions to rinse
with 10 mL of the solution for two minutes four times a
day for 2–5 days.
There are some issues of supply, although most major
hospitals on appropriate request from the patient’s pharmacy,
are happy to supply tranexamic acid. The pharmacy of the
Royal Adelaide Hospital is certainly willing and able to
provide appropriate advice on this.
It is appropriate for the patient’s dentist and the treating
general medical practitioner to review the patient’s
anticoagulation therapy. In our studies, we found over one-
third of patients on warfarin either no longer met the clinical
indications for this therapy, or had an inappropriate dosage
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Professor Woods and Professor Savage, authors of
‘Managing dental patients receiving warfarin therapy’,
comment:
We thank Professor Goss and Dr Carter for drawing attention
to the management of minor oral surgery performed for
patients taking warfarin. Certainly the procedure we
recommend is based on the ‘historical’ approach, it is well
tested, safe and effective. In this respect our recommendations
are consistent with recommendations of Professor Goss and
Dr Carter. Essentially, dental management of patients having
warfarin therapy is a matter of co-operation between dentists
and the physician managing the patient’s coagulation.
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Notwithstanding this comment, the use of tranexamic acid as
a mouthwash is a promising development. The technique has
been tested with a number of favourable reports in the
literature. The present position however, for most dentists
treating patients taking warfarin, is that they have no ready
access to a tranexamic acid mouthwash, there is no proprietary
tranexamic mouthwash available.
For the present, the majority of dentists treating patients
having warfarin therapy have no ready access to or assistance
from a teaching hospital and will in practical terms, have to
rely on the ‘historic’ advice in the Dental Notes.
The heavy drinker in primary care
Editor, – I refer to the article ‘The management of the heavy
drinker in primary care’ (Aust Prescr 2002;25:70–3). This
article is excellent in its succinct coverage of alcohol problems
in general practice. However, I do feel that there is an
underemphasis on the risk of acute thiamine deficiency
even in the general practice population.
In our unit we have recently admitted two male patients with
signs of Wernicke’s encephalopathy. These patients were
both in their mid-forties and had no previous history of
detoxification for alcohol dependence. Both patients had
been transferred from other hospitals where they had been
treated for alcohol withdrawal. The first patient had been a
postoperative inpatient for five days before his transfer and
had been treated for an acute confusional state with
symptomatic medications. He improved within an hour of
his first intramuscular injection of thiamine.
The second patient presented to a local hospital after having
been hit by a car while intoxicated. Once he was medically
stable he was transferred to our Drug and Alcohol Unit and
was found to have a combination of confusion, ataxia,
nystagmus as well as other cerebellar signs. He was so
unwell he was transferred back to the local hospital but he
recalls ‘waking up’ in the ambulance after a single 100 mg
injection of thiamine.
The point is that this is an extremely serious but easily
treatable condition. I would suggest that in Box 2 of Professor
Whelan’s article the use of thiamine be reiterated and if there
is any doubt whatsoever about oral absorption or nutritional
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Professor Greg Whelan, the author of the article, comments:
Dr McNamara rightly brings to our attention the importance
of thiamine given prophylactically in the management of
alcohol withdrawal.
The patients described by him are also seen in our hospital’s
Accident and Emergency service. All patients admitted with
a history of heavy alcohol consumption, whether in alcohol
withdrawal or not, are given an intravenous ‘cocktail’ of
glucose and multivitamins, including thiamine.
The article in Australian Prescriber is aimed at producing
guidance for general practitioners who manage patients in
primary care, not in hospital. As noted, these patients are
given thiamine 100 mg. Our practice is to give this orally
unless we are concerned about absorption.
Medicinal mishaps
Editor, – The case reported in ‘Medicinal mishaps’ (Aust
Prescr 2002;25:73) highlights the importance of obtaining
an accurate medication history as part of the hospital admission
process. Frequently this is ‘easier said than done’. Obtaining
an accurate medication history is often complex, time
consuming and a fallible process. Reasons for this include:
• lack of patient knowledge of their medications
• lists from local doctors and patients that are out of date
• medication labels that are out of date or non specific (‘mdu’)
• transcription errors on residential care facility transfer
letters
• neglecting to ask the patient what they are actually doing
with their medications.
All patients should be encouraged to bring their medications
to every hospital and clinic visit. Patients should be
assisted by their pharmacist, local doctor or family member
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Discontinuation of naproxen suspension
Editor, – Roche Products recently announced plans to
discontinue production of naproxen suspension in Australia.1
Their letter communicating these plans implies that rofecoxib
suspension is a viable alternative. This is irresponsible, for
several reasons, and demonstrates a clear lack of consideration
of the best interests of children.
First, naproxen suspension is currently the most widely used
non-steroidal anti-inflammatory drug (NSAID) in children
with chronic arthropathies worldwide.2 It has a well-
established efficacy and safety profile in children. The liquid
formulation also has a convenient dosage schedule (twice
daily) and is affordable. The only other NSAID with
demonstrated efficacy and safety in children currently
available in liquid formulation in Australia is ibuprofen.
However, its lower effectiveness, need for more frequent
dosing and greater cost are disadvantages in chronic therapy.
The discontinuation of naproxen suspension will therefore
mean that children will be unfairly disadvantaged by having
their already limited NSAID options even further restricted.
Second, children’s risk of significant gastropathy with NSAID
therapy is negligible.3 There is therefore little rationale for
considering a COX-2 inhibitor in the vast majority of children.
Evaluable data regarding their safety/efficacy in children is
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lacking. The question of whether there is any gastrointestinal
safety advantage with COX-2 specific inhibitors4, the emerging
safety concerns in adults5, and the considerably higher cost,
mean that rofecoxib suspension cannot be considered a ‘viable
alternative’ to naproxen suspension for children.
It is time to stop treating children as second class therapeutic
citizens and time to start paying more serious attention to
ensuring that they have fair and equitable access to appropriate
medications.
Madlen Gazarian
Paediatric Clinical Pharmacologist & Rheumatologist
Senior Lecturer, School of Women’s & Children’s Health,




President, Australian and New Zealand Paediatric
Rheumatology Group





President, Royal Australasian College of Physicians (Division
of Paediatrics)
Head, Rheumatology Service, Women’s and Children’s
Hospital
Adelaide
Sensitivity and specificity – is your test reliable?
The reliability of a test depends on the sensitivity and  specificity.
You should ask ‘How am I using this test and how sensitive
and specific is the test?’
The sensitivity of a test is defined as the proportion of people
with disease who have a positive test. A test which is very
sensitive will rarely miss people with the disease. It is important
to choose a sensitive test if there are serious consequences for
missing the disease. Treatable malignancies (in situ cancers or
Hodgkin’s disease) should be found early – thus sensitive tests
should be used in the diagnostic work-up.
The specificity of a test is defined as the proportion of people
without the disease who have a negative test result. A specific
test will have few false positive results – it will rarely misclassify
people without the disease as being diseased. If a test is not
specific, it may be necessary to order additional tests to
confirm a diagnosis.
It is useful for clinicians to know the sensitivity and specificity
of common tests to help in deciding which tests to use to ‘rule
in’ or ‘rule out’ disease. However, predictive values1 are
of more direct clinical usefulness, enabling the clinician
to estimate the probability of disease given the test result.
One problem is that predictive values are prevalence
dependent, but the prevalence (likelihood) of disease can
be increased by clinical signs, other tests and even
clinical ‘intuition’.
Finally, clinical signs and judgement should never be ignored
in the face of a technological test result. For example, if a
suspicious breast lump remains palpable, a negative
mammogram should be ignored.2 In such circumstances,
clinical judgement should suggest biopsy, even though the test
result was negative. Tests are to be used to assist clinicians, not
to rule clinical decision-making.
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Dr David Kingston, Medical Director, Roche Products,
comments:
The decision to discontinue production of Naprosyn
(naproxen) suspension on a global basis was made
because of the discontinuation of one of the flavouring
agents. This meant extensive reformulation work, stability
testing and then registering the new formulation on a
worldwide basis. The low use of Naprosyn suspension led
to the decision to discontinue production. This left
Roche Australia with no source of Naprosyn suspension.
We have been trying to interest some local companies in
producing naproxen suspension but so far there is no
agreement to do so.
We are sorry that it has not been possible to arrange an
alternative supply of naproxen suspension but are
continuing in our efforts.
